Navigation Links
Early Detection Push from New Alzheimer's Disease Discussion Group Points to Advances by Startup Companies, Including Louisville-Based Neuronetrix, Inc.
Date:12/28/2007

LOUISVILLE, Ky., Dec. 28 /PRNewswire/ -- Recent discussions about screening for Alzheimer's disease have begun to stimulate interest in advanced diagnostic technologies. A new advisory group, called AD Screening Discussion Group, has recommended screening for Alzheimer's as patients become eligible for Medicare. The COGNISION(TM) System being developed by Neuronetrix, Inc. is a new Alzheimer's screening technology which will be entering clinical trials in Q1 2008. The COGNISION(TM) System uses proprietary pattern recognition algorithms to classify the patient's brainwave responses based on similarities to known neurological disease profiles. The test is non- invasive, inexpensive, and can be performed in a doctor's office.

Neuronetrix, based in Louisville, KY, will revolutionize the treatment of patients with neurologic disorders by providing meaningful screening information to physicians early in the disease process. Its patent-pending COGNISION(TM) System will "for the first time, directly detect the cognitive deficits associated with Alzheimer's disease," according to K.C. Fadem, inventor of the COGNISION(TM) System.

Alzheimer's is a chronic neurodegenerative disease which afflicts roughly 5 million individuals in the United States. Traditionally, a diagnosis is only made once significant symptoms are present, often 2-4 years into the symptomatic phase of the disease.

"Routine screening is not currently a reality, but it is now appropriate to allow for this, based on the burgeoning senior population in our country and the immense cost to society," according to Dr. Paul R. Solomon, Professor, Department of Psychology and Neuroscience, Williams College; and a member of the AD Screening Discussion Group.

Currently Alzheimer's patients incur direct Medicare/Medicaid costs of more than $50 billion per year, according to the Alzheimer's Association. Mike Reid, CEO of Neuronetrix, indicated that a conservative 5% penetration rate for COGNISION(TM) screening would represent almost $7 billion per year in Americans' cost savings for Alzheimer's care. These savings would be realized by delaying the point at which Alzheimer's sufferers would have to be placed in a long-term care facility. This delay will be due to earlier treatment with current Alzheimer's drugs such as Aricept(R) from Pfizer, Inc. and through treatment with potentially more effective drugs on the near term horizon.

The AD Screening Discussion Group is comprised of a multi-disciplinary panel of experts convened by Eisai Inc., and Pfizer, Inc., to debate the value of screening and early detection for Alzheimer's disease.

For more information, go to http://www.neuronetrix.com.


'/>"/>
SOURCE Neuronetrix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pot bellies linked to early signs of cardiovascular disease
2. Eye-staining technique offers early detection for dry eye syndrome
3. Early Weight Loss in Women Linked to Dementia
4. Isolation of a new gene family essential for early development
5. U of M study: Early treatment can reverse heart damage
6. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Pop stars more than twice as likely to die an early death
9. Exercise and yoga improves quality of life in women with early-stage breast cancer
10. Research says doctors gender may hinder early diagnosis of heart disease in women
11. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 20, 2017 , ... Reflections Recovery Center, a men-only drug ... Joint Commission for chemical dependency and behavioral health services. , The Joint Commission ... that meet the commission’s rigorous standards. Accreditation by The Joint Commission is the ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Doctors on ... to their qualified network of medical professionals working on a personal injury lien basis. ... Spine Surgery Inc brings these esteemed doctors’ vast experience with orthopedic injuries to patients ...
(Date:9/20/2017)... Ohio (PRWEB) , ... September 20, 2017 , ... ... to customer service and innovation, the company recently unveiled a redesigned website. The ... further enrich the work of building owners, architects, contractors and other industry users ...
(Date:9/20/2017)... ... , ... Five consumer packaged goods (CPG) products were selected by the SupplySide ... Nopavera Plus was named to the short list in the Specialty Supplements category. ... presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort in ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive God’s ... emotionally pens his aspirations and goals to better one’s life through God. “The Trials ... while searching in all the wrong places, found a love for writing. Green feels ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
Breaking Medicine Technology: